Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreHarness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.
Harness DataBoost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.
Discover InnovationsNavigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.
Explore MedTechInvest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.
Access InsightsUnlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs.
Unlock InnovationsAccelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions.
Navigate Health PlansLeverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes.
Streamline DecisionsEnhance your ability to evaluate and forecast population risk swiftly and accurately by integrating unmatched data, expertise, and technology.
Evaluate RiskTransform into a data-driven organization that enhances your specialty and showcases value to your members through digital transformation.
Enhance Your SpecialtyA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTSReview the summary of IQVIA's study of the 340B Drug Discount Program examining the program's scale by comparing the number of 340B patients and the revenue from 340B drug discounts to the number of vulnerable individuals. In 2021, 25.9% of healthcare users were 340B patients, with 2.1 to 3.6 times more 340B patients than vulnerable individuals, depending on Medicaid inclusion. This ratio increased for patients using certain Medicare-negotiated drugs. From 2013 to 2021, while the vulnerable population nearly halved, 340B revenue grew by 374%, partly due to the Affordable Care Act, leading to a misalignment between 340B revenue and the size of the vulnerable population.
For the full analysis, please read our white paper here.